Vnitr Lek 2011, 57(11):946-948

Management of obesity - options, effectiveness and perspectives

Š. Svačina
III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA

Weight reduction is an obvious aim of the obesity treatment. However, modern obesitology emphasises prevention of complications associated with obesity and improving the quality of life of obese patients. Consequently, obesity is a difficult to treat disease with respect to permanent weight reduction and easier to treat condition with respect to the quality of life. Life style changes usually fail as a treatment option, unless they are accompanied with personally demanding psychotherapy and motivational support. Compliance with the requirements for diabetes prevention is effective even without weight reduction. Treatment with anti-obesity medication and bariatric surgery are also associated with long-term effectiveness. However, orlistat is the only anti-obesity agent currently available. New anti-obesity medication with central effect that would replace no longer used sibutramin, are expected to reach clinical practice in a few years. The effect of incretin analogues on weight reduction also provides hope. Physical activity has the best effect on obese patients' prognosis. Nonetheless, the future of obesity treatment is mainly associated with pharmacotherapy and new technologies, e.g. gastric stimulation.

Keywords: obesity; quality of life; diabetes prevention; anti-obesity agents; incretin analogues; bariatric surgery; gastric stimulation

Received: October 21, 2011; Published: November 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svačina Š. Management of obesity - options, effectiveness and perspectives. Vnitr Lek. 2011;57(11):946-948.
Download citation

References

  1. Lajka J. Výsledky výzkumu obezity v ČR. Projekt VZOP Žij zdravě. STEM/MARK Praha 2011.
  2. Svačina Š. Prevence diabetu a jeho komplikací. Praha: Triton 2008.
  3. Smith SROV, Weissman NJ, Anderson CM et al. Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 245-256. Go to original source... Go to PubMed...
  4. Svačina Š. Obezita diabetes. Praha: Maxdorf 2000.
  5. Anderson JW. Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage. Expert Opin Pharmacother 2007; 8: 1733-1742. Go to original source... Go to PubMed...
  6. Haluzík M, Svačina Š. Inkretinová léčba diabetu. Praha: Mladá Fronta 2010.
  7. Fried M et al. Metabolická a chirurgická léčba obezity. Praha: Mladá Fronta 2011.
  8. Svačina Š et al. Poruchy metabolismu a výživy. Praha: Galén 2010.
  9. Unick JL, Beavers D, Jakicic JM et al. Look AHEAD Research Group. Effectiveness of Lifestyle Interventions for Individuals With Severe Obesity and Type 2 Diabetes: Results from the Look AHEAD trial. Diabetes Care 2011; 34: 2152-2157. Go to original source... Go to PubMed...
  10. Sanmiguel CP, Conklin JL, Cunneen SA et al. Gastric electrical stimulation with the TANTALUS System in obese type 2 diabetes patients: effect on weight and glycemic control. J Diabetes Sci Technol 2009; 3: 64-970. Go to original source... Go to PubMed...
  11. Paxman JR, Richardson JC, Dettmar PW et al. Daily ingestion of alginate reduces energy intake in free-living subjects. Appetite 2008; 51: 713-719. Go to original source... Go to PubMed...
  12. Philadelphia Business Journal. Startup Aspire inspired by its weight-loss device. Available at: http://www.bizjournals.com/philadelphia/print-edition/2011/03/25/startup-aspire-inspired-by-its.html.
  13. Haluzík M, Svačina Š. Metabolický syndrom a nukleární receptory. Praha: Grada 2005.
  14. Kirkham TC, Steven J. Appetite and Body Weight. Integrative Systems and the Development of Anti-Obesity Drugs. Amsterdam: Elsevier 2007.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.